CCCC News and Press, C4 Therapeutics Inc. From 04/29/24

WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compe...

2024-04-26 15:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the Stifel 2024 Targe...

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research (AACR) Annual Meeting 2...

2024-04-06 20:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the acceptance of two preclinical poster presentations at the American Associati...

Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research Costs Under the Collaboratio n C4T Eligible for up to Approximately $...

2024-02-28 11:36:23 ET DENVER, Colo., Feb 28, 2024 ( 247marketnews.com )- C4 Therapeutics (NASDAQ: CCCC ) hit another new 52-week high, today, and is continuing a run, which we started covering when it was trading at $1.54, following its license and research collaboration with Merck...

2024-02-23 09:39:41 ET DENVER, Colo., Feb 23, 2024 (www.247marketnews.com)- C4 Therapeutics (NASDAQ: CCCC ), Kraig Biocraft Laboratories (OTCQB: KBLB ), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), and NVIDIA (NASDAQ: NVDA ) were among the listings that hit new 52-week hig...

2024-02-22 14:04:23 ET DENVER, Colo., Feb 22, 2024 ( 247marketnews.com ) – ( NASDAQ:CCCC ) discussed in this article. CCCC just hit a high of $8.72 with more than usual volume of just over 4 million after filing the annual report. Read the filing here About C4 T...